^
    Back
    Association details:
    Biomarker:TFG-ALK fusion
    Cancer:Multiple Myeloma
    Drug Class:ALK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    NPJ Genome Med
    Title:

    Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

    Published date:
    03/17/2021
    Excerpt:
    Here, we report a case of a patient with relapsed and refractory NSMM with brain metastasis harboring a TFG-ALK fusion showing a dramatic and durable (over two years) response to commercially available anaplastic lymphoma kinase (ALK) inhibitors.
    DOI:
    10.1038/s41525-021-00186-9